蔗糖铁注射液治疗缺铁性贫血的临床观察

Clinical observation of Iron Sucrose Injection in treatment of iron deficiency anemia

目的观察蔗糖铁注射液治疗缺铁性贫血的临床疗效以及不良反应。方法选取郑州人民医院血液肿瘤科于2011年5月—2013年2月入院的缺铁性贫血患者62例,随机分为治疗组(34例)和对照组(28例),对照组患者口服琥珀酸亚铁片200 mg/次,3次/d,直至血红蛋白及铁蛋白恢复正常。治疗组患者给予2支蔗糖铁注射液稀释于200 mL生理盐水中,静脉点滴至少30 min以上,首次使用时将上述20 mL液体(相当于20 mg蔗糖铁注射液)滴注15 min以上,若患者没有发生过敏反应,剩余剂量则在30 min以上点滴完成,每周3次,直至完成预计补铁量;治疗结束后,比较两组的临床疗效和不良反应发生情况,同时计算患者的治疗时间和纠正贫血所需时间。结果治疗组和对照组总有效率均为100%,治疗组治愈率为100%,对照组为92.9%,两组差异有统计学意义(P<0.05)。治疗组治疗时间和纠正贫血所需时间均明显短于对照组(P<0.05)。治疗组不良反应发生率为5.9%,对照组为14.3%,两组比较差异有统计学意义(P<0.05)。结论蔗糖铁注射液治疗缺铁性贫血具有较好的临床疗效,且安全性较好。

Objective To explore the clinical effects and adverse reaction of Iron Sucrose Injection in the treatment of iron deficiency anemia （IDA）. Methods The patients （62 cases） diagnosed with IDA in People＇s Hospital of Zhengzhou from May 2011 to February 2013 were randomly divided into treatment （34 cases） and control （28 cases） groups. The patients in the control group were po administered with Ferrous Succinate Tablets （200 mg） for three times daily, until hemoglobin and ferritin were normal. The patients in the treatment group were iv administered with 200 mg Iron Sucrose Injection which was diluted in 200 mL physiological saline for at least 30 min or more. At the first time, 20 mL of liquid （20 mg Iron Sucrose Injection） was injected in 15 min or more, if the patients did not occur allergic reactions, the remain dosage was injected in more than 30 min, three times every week until the expected amount of iron was completed. After the treatment, the clinical efficacy and adverse reactions in the two groups were compared, the treatment time and the time of anemia correction were calculated. Results After the treatment, the efficacies in the treatment and control groups were both 100%, and the curative rates in the treatment and control groups were 100% and 92.9%, respectively, with the significant difference between the two groups （P 〈 0.05）. The treatment time and the time of anemia correction in the treatment group were significantly shorter than those in the control group （P 〈 0.05）. The rates of adverse reactions in the treatment and control groups were 5.9% and 14.3%, with the significant difference between the two groups （P 〈 0.05）. Conclusion Iron Sucrose Injection has better clinical efficacy in the treatment of IDA, and the therapeutic effect is reliable and safe.